Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > ARCHIVE
ARCHIVE
- REGULATORY NEWS IN BRIEF
December 18, 2006
- Japanese Gov't Asks for Regular Meetings Between Japanese Companies and US FDA
December 18, 2006
- Institute Issues Proposals to Promote Regenerative Medicine
December 18, 2006
- Kenporen Preparing Pamphlet on Generic Drugs
December 11, 2006
- GENERIC NEWS IN BRIEF
December 11, 2006
- Terumo's Triplex Artificial Blood Vessel Recommended for Approval
December 11, 2006
- Criteria Established for "Observation Services"
December 11, 2006
- PhRMA
December 11, 2006
- NEW PRODUCTS
December 11, 2006
- Survey Reveals Major Gap in New Drug Access in US/EU vs. Japan
December 11, 2006
- MEDICAL DEVICE NEWS IN BRIEF
December 11, 2006
- 4 New Drugs Recommended for Approval by 2nd Committee on Drugs
December 11, 2006
- NEW PRODUCTS
December 11, 2006
- 9 New Drugs Recommended for Approval by 1st Committee on Drugs
December 11, 2006
- SSP Plans to Develop OTC Drugs Using Western Herbs
December 11, 2006
- IHOKEN FORUM 2006
December 11, 2006
- SURVEY of Korosho
December 11, 2006
- REGULATORY NEWS IN BRIEF
December 11, 2006
- Addition of Guidant Enhances Abbott Vascular's Global Presence: Mr D. C. Bryant
December 11, 2006
- TOPIC an article
December 11, 2006
ページ
Japan will overhaul its R&D tax credit regime in its FY2026 reform, introducing a new strategic category alongside existing frameworks.…
Strategic Talent Acquisition in the Japanese Life Sciences Sector: Your Market Intelligence Briefing
Focus: How to Get the Talent You Need in a Tough MarketThe Japanese life sciences sector presents a challenging landscape for global companies. To succeed, you must move beyond reactive hiring and adopt a truly strategic talent acquisition model. Our…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…